Indivior Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.2B | $1.2B | $1.1B | $901.0M | — |
| Cost of revenue | $246.0M | $231.0M | $174.0M | $151.0M | — |
| Gross profit | $994.0M | $957.0M | $919.0M | $749.0M | — |
| Selling, general & administrative | $634.0M | $612.0M | $565.0M | $469.0M | — |
| Research and development | $97.0M | $107.0M | $116.0M | $74.0M | — |
| Operating expenses | — | $919.0M | $1.1B | $831.0M | — |
| Operating income | $262.0M | $38.0M | -$152.0M | -$81.0M | — |
| Interest expense | $45.0M | $41.0M | $35.0M | $27.0M | — |
| Pretax income | $239.0M | $20.0M | -$145.0M | -$89.0M | — |
| Income tax expense | $29.0M | $13.0M | -$19.0M | -$44.0M | — |
| Net income | $210.0M | $7.0M | -$126.0M | -$44.0M | — |
| Balance Sheet | |||||
| Cash and equivalents | $195.0M | $319.0M | $316.0M | — | — |
| Current assets | $652.0M | $827.0M | $1.3B | — | — |
| Total assets | $1.2B | $1.3B | $1.8B | — | — |
| Current liabilities | $914.0M | $924.0M | $1.3B | — | — |
| Total liabilities | $1.3B | $1.7B | $1.9B | — | — |
| Stockholders' equity | -$98.0M | -$337.0M | -$184.0M | -$15.0M | $121.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$27.0M | $36.0M | -$300.0M | -$4.0M | — |
| Depreciation and amortization | $10.0M | $16.0M | $15.0M | $16.0M | — |
| Stock-based compensation | $26.0M | $24.0M | $21.0M | $16.0M | — |
| Capital expenditure | $66.0M | $29.0M | $8.0M | $5.0M | — |
| Free cash flow | -$93.0M | $7.0M | -$308.0M | -$9.0M | — |
| Share repurchases | $11.0M | $173.0M | $33.0M | $90.0M | — |
| Impairments | $19.0M | $8.0M | $0 | $0 | — |
Shares outstanding 121.9M · Free float 90.3%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.